Entera Bio Ltd.

Healthcare · Biotechnology · Israel

Last price 3.2 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 556.55M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist pept...